APTO:NSD-Aptose Biosciences Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 6.13

Change

0.00 (0.00)%

Market Cap

USD 0.54B

Volume

0.39M

Average Target Price

USD 11.00 (+79.45%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1b clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase 1a/b clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD56.71B 21.08 16.42
REGN Regeneron Pharmaceuticals, Inc

N/A

USD54.24B 20.76 16.02
MRNA Moderna, Inc

N/A

USD43.20B N/A N/A
SGEN Seagen Inc

N/A

USD29.62B 65.69 65.81
ALXN Alexion Pharmaceuticals, Inc

N/A

USD26.98B 28.36 26.40
RPRX Royalty Pharma plc

N/A

USD25.62B 22.60 9.61
BGNE BeiGene, Ltd

N/A

USD25.22B N/A N/A
BNTX BioNTech SE

N/A

USD24.53B -99,999.99 N/A
GMAB Genmab A/S

N/A

USD23.24B 26.59 2.65
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing APTO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.11% 54% F 59% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.11% 53% F 58% F
Trailing 12 Months  
Capital Gain 122.91% 83% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 122.91% 83% B 90% A-
Trailing 5 Years  
Capital Gain 99.67% 81% B- 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 99.67% 81% B- 76% C
Average Annual (5 Year Horizon)  
Capital Gain 55.85% N/A N/A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.85% N/A N/A 93% A
Risk Return Profile  
Volatility (Standard Deviation) 115.51% N/A N/A 8% F
Risk Adjusted Return 48.35% N/A N/A 69% D+
Market Capitalization 0.54B 65% D 57% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.05 50% F 34% F
Price / Cash Flow Ratio -25.23 84% B 88% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -61.61% 53% F 19% F
Return on Invested Capital -49.73% 61% D- 19% F
Return on Assets -36.44% 32% F 9% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.82 72% C- 68% D+
Short Percent 2.58% 76% C 55% F
Beta 0.85 79% C+ 68% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.